Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938783 | 0.83 | — | — | |
| SCHEMBL939200 | 0.78 | CA2 (0.31) | — | |
| SCHEMBL940369 | 0.72 | NQO1 (0.38) | RAB9A | |
| SCHEMBL4918466 | 0.67 | — | — | |
| SCHEMBL4919014 | 0.66 | — | — | |
| SCHEMBL1967214 | 0.66 | — | — | |
| SCHEMBL8513640 | 0.64 | — | — | |
| SCHEMBL7975988 | 0.64 | — | — | |
| SCHEMBL4878178 | 0.63 | NOS3 (0.34) | NOS3NOS1NOS2 | |
| SCHEMBL2654847 | 0.61 | MEN1 (0.40) | CYP1A1CYP1B1MEN1KMT2APDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373825-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | claimed |
| US-20230303584-A1 | 4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE SUMO INHIBITORS AND USES THEREOF | CIT THERAPEUTICS LLC | 2023-09-28 | — | — | US | claimed |
| CN-111566109-B | 2,4,6, 7-tetrahydropyrazolo [4,3-d ] pyrimidin-5-one derivatives and related compounds for the treatment of vasculitis and inflammatory diseases | 爱杜西亚药品有限公司 | 2023-07-11 | — | — | CN | claimed |
| US-20230192708-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-22 | — | — | US | claimed |
| WO-2023004376-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2023-01-26 | — | — | WO | claimed |
| WO-2021150918-A1 | 4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE SUMO INHIBITORS AND USES THEREOF | ONCOVALENT THERAPEUTICS INC. (US) | 2021-07-29 | — | — | WO | claimed |
| US-20200369672-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | IDORSIA PHARMACEUTICALS LTD. (CH) | 2020-11-26 | — | — | US | claimed |
| CN-111566109-A | 2,4,6, 7-tetrahydropyrazolo [4,3-d ] pyrimidin-5-one derivatives and related compounds as C5a receptor modulators for the treatment of vasculitis and inflammatory diseases | 爱杜西亚药品有限公司 | 2020-08-21 | — | — | CN | claimed |
| US-8003798-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | NYCOMED GMBH (DE) | 2011-08-23 | — | — | US | claimed |
| US-20080167316-A1 | 6-Heteroaryl-1,2,3,4,4A, 10B-Hexahydrophenanthridines as Pde4-Inhibitors for the Treatment of Inflammatory Disorders | ALTANA PHARMA AG (DE) | 2008-07-10 | — | — | US | claimed |
| US-20080167301-A1 | Respiratory system disorders | ALTANA PHARMA AG (DE) | 2008-07-10 | — | — | US | claimed |
| EP-1856092-A1 | 6-HETEROARYL-1,2,3,4,4A,10B-HEXAHYDRO-PHENANTHRIDINES AS PDE-4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Nycomed GmbH (DE) | 2007-11-21 | — | — | EP | claimed |
| EP-1723135-A1 | NOVEL HYDROXY-6-HEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | Altana Pharma AG (DE) | 2006-11-22 | — | — | EP | claimed |
| WO-2006092417-A1 | 6 -HETEROARYL-1, 2, 3,4,4A, 1OB-HEXAHYDRO-PHENANTHRIDINES AS PDE-4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | NYCOMED GMBH (DE) | 2006-09-08 | — | — | WO | claimed |
| WO-2005085225-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-15 | — | — | WO | claimed |
| EP-4373825-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| EP-4367110-A1 | NEW SELECTIVE ANGIOTENSIN II COMPOUNDS | Vicore Pharma AB (SE) | 2024-05-15 | — | — | EP | disclosed |
| US-4654074-A | 2-chloro-N-(4,6-dimethoxy-5-pyrimidinyl)-N-[1,(1-pyrazolyl)ethyl]acetamide, herbicidal composition comprising said compound, and method of controlling weeds using said compound | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1987-03-31 | — | — | US | disclosed |
| EP-0195259-A1 | 2-Chloro-N-(4,6-dimethoxy-5-pyrimidinyl)-N-[1-(1-pyrazolyl)ethyl]acet-amide, herbicidal composition comprising said compound, and method of controlling weeds using said compound | MITSUBISHI PETROCHEMICAL CO., LTD. (JP) | 1986-09-24 | — | — | EP | disclosed |
| EP-0136702-A2 | Cyclohexenol derivatives, process for their preparation and their use in combating undesirable plant growth | BASF Aktiengesellschaft (DE) | 1985-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303584-A1 | 4,5,6,7-TETRAHYDROTHIENO[2,3-C]PYRIDINE SUMO INHIBITORS AND USES THEREOF | SUMO1, SUMO3, SUMO2 | CYP1A1 544/4885CYP1B1 1243/4885MEN1 2719/4885 |
| US-20080167316-A1 | 6-Heteroaryl-1,2,3,4,4A, 10B-Hexahydrophenanthridines as Pde4-Inhibitors for the Treatment of Inflammatory Disorders | PDE4A, PDE4B, PDE4C | CYP1A1 67/4885CYP1B1 38/4885MEN1 4619/4885 |
| US-20080167301-A1 | Respiratory system disorders | PDE4A, PDE4B, PDE12 | CYP1A1 218/4885CYP1B1 233/4885MEN1 3929/4885 |
| US-20200369672-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | C3AR1, C5AR1, C5AR2 | CYP1A1 411/4885CYP1B1 643/4885MEN1 1430/4885 |
| US-20230192708-A1 | 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES | C3AR1, C5AR1, C5AR2 | CYP1A1 411/4885CYP1B1 643/4885MEN1 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.